Issue link: https://www.e-digitaleditions.com/i/1199406
8 January 2020 Tablets & Capsules research Study finds no adverse health effects from titanium dioxide EAST LANSING, MI—A study conducted by investigators at the Center for Research on Ingredient Safety at Michigan State Univer- sit y (MSU) in collaboration with the University of Nebraska Med- ical Center (UNMC) showed no evidence that food-grade titanium dioxide (E 171) causes adverse health outcomes for consumers. The study was conducted to address the meth- odological flaws of a previous study published in 2017 in the multidisci- plinary journal Scientific Reports. T he original st udy found that oral administration of E 171 to rats produced lesions in the colon and changed the rodents' immune sys- tems. When the study was reviewed by th e E u r o p e a n F o o d S a f e t y A u th or it y ( E F S A), th e a g e n c y determined that the study had seri- ous methodolog ical f laws, s uch as administering the ingredient in drinking water despite E 171 being insoluble in water and not present in any liquid food products. T he MSU and U NMC teams administered E 171 to rats for 7 and 100 days in the diet using multiple doses, which were less than, simi- lar to, and greater than those used in the 2017 st udy. More impor- tantly, the study was conducted in a blinded manner such that the inves- tigative team did not know which tissues came from which experimen- tal animals until the analysis of all biological samples was completed to eliminate the possibility of experi- mental bias. MSU and UNMC sci- entists were unable to demonstrate any adverse effects due to E 171. T he st udy was published in the November 2019 edition of the jour- nal Food and Chemical Toxicology. markets Generic pharma market to exceed $309 billion by 2022 PHILADELPHIA, PA—The global generic pharmaceuticals market is expected to grow at a compound annual rate of 9.3 percent through 2022 and will reach $309.16 billion, according to a report by Business Research. The rise of chronic diseases and the increasing costs of branded pharmaceutical products will drive market growth. 3D printing will also aid in the appeal of generics, as the technology allows manufacturers to produce drug products with custom- ized sizes, shapes, and textures, as well as different release rates, appear- ances, and tastes. Key market players include Teva Pharmaceuticals, Mylan, Sandoz International, Hospira, and Sun Pharmaceutical. Demand for pharmaceutical equipment to increase through 2025 CITY OF INDUSTRY, CA—The global pharmaceutical equipment market is expected to reach $51.3